Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). The company also offers contract manufacturing and laboratory services.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). The company also offers contract manufacturing and laboratory services.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma. EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. The drug candidate is also under development for castration-resistant prostate cancer in the Japan as a tablet formulation.

Hormones 113

Hormones Contract Manufacturing Manufacturing Development 113

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Myelofibrosis. EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. The drug candidate is also under development for castration-resistant prostate cancer in the Japan as a tablet formulation.

Hormones 100

Hormones Contract Manufacturing Manufacturing Development 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.

Hormones 100

Hormones Contract Manufacturing Manufacturing Development 100

XTalks

JANUARY 23, 2024

Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development.

Development 72

Development Hormones Drugs Trials 72

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. Manufacturing for Wegovy was also hit when a contract manufacturer in charge of syringe filling halted deliveries due to issues with good manufacturing practices.

Drugs 264

Drugs Manufacturing Hormones Contract Manufacturing 264